

EXPRESSION OF BCL-2 AND KI-67 IN COLORECTAL CARCINOMA

Immunohistochemical and Histopathological Study

Thesis

Submitted For Partial Fulfillment of The Requirement of M.D Degree in
Pathology

By: Sara EL-Sayed Khalifa

M.B.B.Ch, M.Sc., Cairo University

Supervisors

Prof. Dr. Naiema Abdel Moniem Marie

Professor & Former Head of Pathology Department

Faculty of Medicine, Cairo University

Prof. Dr. Ali Ahmed Foad El-Hindawi

Professor & Head of Pathology Department

Faculty of Medicine, Cairo University

Dr. Sahar Abdel Hamid Tabak

Lecturer of Pathology

Faculty of Medicine, Cairo University

Faculty of Medicine

Cairo University

2012

ACKNOWLEDEMENT

First and foremost thanks to God, the most beneficent and merciful.

I would like to express my sincere gratitude and deepest appreciation to Prof. Dr. Naiema Abdel Moniem Marie, Professor & Former Head of Pathology Department, Faculty of Medicine, Cairo University for her generous supervision, valuable advices, constructive criticism and indispensable help throughout this work.

My profound thanks and appreciation goes to Prof. Dr. Ali Ahmed Foad El-Hindawi, Professor & Head of Pathology Department, Faculty of Medicine, Cairo University for his kind supervision, real assistance, and great effort in overcoming all obstacles that faced this work.

I would like to express my sincere gratitude and appreciation to Dr. Sahar Abdel Hamid Tabak, Lecturer of Pathology, Faculty of Medicine, Cairo University for her meticulous supervision, valuable criticism and sincere support all through the work.

At last but not least I would like to thank my family members who were behind me in every successful step in my life, my mother, my father, my sister, and my dear husband. They exerted true effort in helping me to complete this work

The Candidate.

ABSTRACT

Background: It is widely recognized that colorectal tumors of the same pathologic stage can produce considerably different clinical outcomes. Further identification of other factors that influence aggressiveness of the tumor are recommended. Cell proliferation and cell loss both determine the rate of volume increase of a tumor. Bcl-2 is an anti apoptotic marker and Ki-67 is a proliferation marker. **Aim of the Work:** This study aims at evaluation of expression of Bcl-2 and Ki-67 markers in colorectal carcinoma. **Material & Methods:** Evaluation of expression of Bcl-2 and Ki-67 markers in 60 cases of colorectal carcinoma was performed. **Results:** The commonest histologic type detected was adenocarcinoma (80%), followed by signet-ring cell carcinoma (10%), mucinous adenocarcinoma (8.3%), and undifferentiated carcinoma (1.7%), (P value <0.01). Histopathologic features including histological grade, local tumor extension, and lymph node involvement were found to have a statistically significant correlation with different colorectal carcinoma histopathologic types. 61.7% of the studied colorectal carcinoma cases were considered bcl-2 negative, and 38.3% were considered bcl-2 positive. Among positive cases 25% showed mild bcl-2 positivity, 11.7% showed moderate bcl-2 positivity, while only 1.7% displayed marked bcl-2 positivity with a statistically significant difference, (p value <0.01). The Ki-67 proliferation index values ranged from 0-100% with a mean of $65.57 \pm 32.829\%$ and a median of 80%. **Conclusions & Recommendations:** Neither Bcl-2 nor Ki-67 is statistically related to age of patients, sex, clinical presentation, tumor site, gross appearance, histopathologic types, histological grade, local tumor extension, nodal involvement, and staging. Further investigations with a higher number of cases are needed to confirm the real significance of Bcl-2 and Ki-67 in colorectal cancer.

Key Words: Bcl-2, Ki-67, colorectal carcinoma.

LIST OF ABBREVIATION

ACI: Amsterdam Criteria I
ACII: Amsterdam criteria II
AJCC: American Joint Committee on Cancer
ANOVA: analysis of variance
APC: adenomatous polyposis coli
BAX: Bcl-2-associated X protein
Bcl-2: B-cell lymphoma-2
BMI: body mass index
BrdU: 5-bromodeoxyuridine
BrdUrd: bromodeoxyuridine
CDKs: cyclin-dependent kinases
CHRPE: congenital hypertrophy of the retinal pigment epithelium
C-myc: oncogene
CRC: colorectal carcinoma
CRM: circumferential resection margin
CTC: computed tomographic colonography
DAB: diaminobenzidine
DALM: dysplasia associated lesion or mass
DCBE: double-contrast barium enema
DCC: deleted in colon cancer
dH₂O: distilled water
DNA: deoxy ribonucleic acid
FAP: familial adenomatous polyposis coli
FOBT: fecal occult blood test
FSIG: flexible sigmoidoscopy
G1 phase: gap 1 phase
H₂O₂: hydrogen peroxide
HNPCC: hereditary non polyposis colorectal cancer
HPF: high-power fields
IARC: International Agency for Research on Cancer
ICG-HNPCC: International Collaborative Group on HNPCC
IGF2: Insulin-like growth factor 2
IUrd: iododeoxyuridine

JP: Juvenile polyposis
K-ras: oncogene
LI: labeling index
LOH: loss of heterozygosity,
mAb: monoclonal antibody
MAP kinase: Mitogen-activated protein kinase
MMP7: matrix metalloproteinase 7
MMR: Mismatch Repair
MSI: microsatellite instability
MSI-H: high-frequency MSI
MSI-L: low-frequency MSI
MSS: microsatellite stable
P value: probability factor
p16: tumor suppressor
P53: tumor suppressor gene
PBS: phosphate buffered saline
PCNA: proliferating cell nuclear antigen
PET: positron emission tomography
PPARs: peroxisome proliferator-activated receptors
S100A4: metastasis promoting gene
SMADs: tumor suppressor
SPF: S-phase fraction
SPSS: Statistical Product for Services Solutions
TA: transitamplifying
TGF- β : transforming growth factor beta
TGF β R-II: transforming growth factor beta receptor-II
TME: total mesorectal excision
Tpot: potential doubling time
Ts: duration of S-phase
UC: ulcerative colitis
UICC: Union International Contre Le Cancer)
WHO: World Health Organization

LIST OF TABLES

No.	Title	Page
Review of literature		
Table (1)	Subsites of the colon and rectum.	4
Table (2)	Genetic changes associated with CRC development.	12
Table (3)	Risk factors for colorectal cancer.	18
Table (4)	Features of HNPCC.	21
Table (5)	Revised diagnostic criteria for HNPCC (Amsterdam criteria II), (ACII).	22
Table (6)	Recommended options for colorectal cancer screening in asymptomatic, average-risk individuals	33
Table (7)	World Health Organization (WHO) (2000) histologic classification of colorectal carcinoma.	36
Table (8)	Grading of adenocarcinomas of the colon and rectum.	41
Table (9)	Histopathologic grading systems in colorectal carcinoma.	43
Table (10)	TNM classification of tumours of the colon and rectum.	45
Table (11)	TNM stage grouping of tumours of the colon and rectum.	46
Table (12)	Methods of measuring proliferation.	67
Results		
Table (13)	Age characteristics in studied colorectal carcinoma cases.	81
Table (14)	Sex distribution in studied colorectal carcinoma cases.	82
Table (15)	Clinical presentation in studied colorectal carcinoma cases.	83
Table (16)	Site of the tumor in studied colorectal carcinoma cases.	84
Table (17)	Gross appearance in the studied colorectal carcinoma cases.	85
Table (18)	Histopathologic types of the studied colorectal carcinoma cases.	87
Table (19)	Age distribution of studied colorectal carcinoma cases in relation to histopathologic type.	88
Table (20)	Sex distribution of the studied colorectal carcinoma cases in relation to histopathologic type.	89
Table (21)	Clinical presentation in relation to histopathologic type.	90

Table (22)	Site of studied colorectal carcinoma cases in relation to histopathologic type.	91
Table (23)	Gross appearance of studied cases of colorectal carcinoma in relation to histopathologic type.	93
Table (24)	Histologic grade of studied colorectal carcinoma cases.	94
Table (25)	Histological grade of studied colorectal carcinoma cases in relation to histopathologic type.	95
Table (26)	Local tumor extension of studied colorectal carcinoma cases.	96
Table (27)	Local tumor extension of studied colorectal carcinoma cases in relation to histopathologic types.	97
Table (28)	Nodal involvement of studied colorectal carcinoma cases.	98
Table (29)	Nodal involvement in studied colorectal carcinoma cases with regard to histopathologic types.	99
Table (30)	TNM stage grouping of the studied colorectal carcinoma cases.	101
Table (31)	TNM stage grouping in histopathologic types of studied colorectal carcinoma cases.	102
Table (32)	Bcl-2 immunoreactivity in studied colorectal carcinoma cases.	104
Table (33)	Age distribution of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity.	105
Table (34)	Sex distribution among bcl-2 immunoreactivity classes of colorectal carcinoma studied cases.	106
Table (35)	Clinical presentation of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	107
Table (36)	Site of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	109
Table (37)	Gross appearance of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	111
Table (38)	Bcl-2 immunoreactivity in relation to studied colorectal carcinoma histopathologic types.	113
Table (39)	Histological grade of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	115
Table (40)	Local tumor extension of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	117
Table (41)	Nodal involvement in different bcl-2 immunoreactivity classes in studied colorectal carcinoma cases.	119
Table (42)	TNM stage grouping in bcl-2 immunoreactivity classes of studied cases of colorectal carcinoma.	121
Table (43)	Ki-67 proliferation index in studied cases.	123

Table (44)	Ki-67 proliferation indices distribution in relation to sex of patients in colorectal carcinoma studied cases.	123
Table (45)	Ki-67 proliferation indices distribution in relation to clinical presentation of colorectal carcinoma cases studied	124
Table (46)	Ki-67 proliferation indices distribution in relation to tumor location in colorectal carcinoma studied cases.	125
Table (47)	Ki-67 proliferation indices distribution in relation to gross appearance in colorectal carcinoma studied cases.	127
Table (48)	Ki-67 proliferation indices distribution of colorectal carcinoma studied cases in relation to histopathologic type.	128
Table (49)	Ki-67 proliferation indices distribution of colorectal carcinoma studied cases in relation to histological grade.	130
Table (50)	Distribution of Ki-67 proliferation indices of colorectal carcinoma studied cases in relation to local tumor extension.	131
Table (51)	Ki-67 proliferation indices distribution of the studied colorectal carcinoma cases in relation to lymph nodes involvement.	132
Table (52)	Ki-67 proliferation indices distribution of studied colorectal carcinoma cases in relation to the TNM stage grouping.	133
Table (53)	Ki-67 proliferation indices distribution of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	134

LIST OF GRAPHS

No.	Title	Page
Review of literature		
Diagram (1)	Colonic crypt organization.	7
Diagram (2)	Model for the adenoma-carcinoma sequence of CRC.	14
Diagram (3)	Phases of the cell cycle.	71
Results		
Graph (1)	Sex distribution in studied colorectal carcinoma cases.	82
Graph (2)	Clinical presentation in studied colorectal carcinoma cases.	83
Graph (3)	Site of the tumor in studied colorectal carcinoma cases.	84
Graph (4)	Gross appearance in studied colorectal carcinoma cases.	85
Graph (5)	Histopathologic types in studied colorectal carcinoma cases.	87
Graph (6)	Sex distribution of studied colorectal carcinoma cases in relation to histopathologic type.	89
Graph (7)	Clinical presentation of studied colorectal carcinoma cases in relation to histopathologic type.	90
Graph (8)	Site of studied colorectal carcinoma cases in relation to histopathologic type.	92
Graph (9)	Gross appearance of studied colorectal carcinoma cases in relation to histopathologic type.	93
Graph (10)	Histologic grade of studied colorectal carcinoma cases.	94
Graph (11)	Histological grade of studied colorectal carcinoma cases in relation to histopathologic type.	95
Graph (12)	Local tumor extension of studied colorectal carcinoma cases.	96
Graph (13)	Local tumor extension of colorectal carcinoma cases in relation to histopathologic types.	97

Graph (14)	Nodal involvement of studied colorectal carcinoma cases.	98
Graph (15)	Nodal involvement in studied colorectal carcinoma histopathologic types.	100
Graph (16)	TNM stage grouping of studied colorectal carcinoma cases.	101
Graph (17)	TNM stage grouping in studied colorectal carcinoma histopathologic types.	103
Graph (18)	Bcl-2 immunoreactivity in studied colorectal carcinoma cases.	104
Graph (19)	Sex distribution among bcl-2 immunoreactivity classes in the studied colorectal carcinoma cases.	106
Graph (20)	Clinical presentation of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	108
Graph (21)	Site of colorectal carcinoma studied cases in relation to bcl-2 immunoreactivity classes.	110
Graph (22)	Gross appearance of colorectal carcinoma studied cases in relation to bcl-2 immunoreactivity classes.	112
Graph (23)	Bcl-2 immunoreactivity in relation to studied colorectal carcinoma types.	114
Graph (24)	Histological grade of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	116
Graph (25)	Local tumor extension of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	118
Graph (26)	Nodal involvement of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	120
Graph (27)	TNM stage grouping in bcl-2 immunoreactivity classes of studied colorectal carcinoma cases.	122
Graph (28)	Ki-67 proliferation indices distribution in relation to sex of patients in colorectal carcinoma studied cases.	123
Graph (29)	Ki-67 proliferation indices distribution in relation to clinical presentation of colorectal carcinoma cases studied.	124

Graph (30)	Ki-67 proliferation indices distribution in relation to tumor location in colorectal carcinoma studied cases.	126
Graph (31)	Ki-67 proliferation indices distribution in relation to gross appearance in colorectal carcinoma studied cases.	127
Graph (32)	Ki-67 proliferation indices distribution of colorectal carcinoma studied cases in relation to histopathologic type.	129
Graph (33)	Ki-67 proliferation indices distribution of colorectal carcinoma studied cases in relation to histological grade.	130
Graph (34)	Distribution of Ki-67 proliferation indices of colorectal carcinoma studied cases in relation to local tumor extension.	131
Graph (35)	Ki-67 proliferation indices distribution of the studied colorectal carcinoma cases in relation to lymph nodes involvement.	132
Graph (36)	Ki-67 proliferation indices distribution of studied colorectal carcinoma cases in relation to the TNM stage grouping.	133
Graph (37)	Ki-67 proliferation indices distribution of studied colorectal carcinoma cases in relation to bcl-2 immunoreactivity classes.	134

LIST OF FIGURES

No.	Title	Page
Fig (1)	Colorectal adenocarcinoma grade II composed of irregular shaped glands lined by malignant epithelial columnar cells with overlapping nuclei. (H & E x100)	135
Fig (2)	Colorectal adenocarcinoma grade II with back to back arrangement of the malignant glands. (H & E x100)	135
Fig (3)	Colorectal adenocarcinoma grade II with a cribriform pattern infiltrating muscle fibres. (H & E x100)	136
Fig (4)	Colorectal adenocarcinoma grade III formed of small groups & solid sheets of malignant epithelial cells with attempt at acinar formation. Necrosis and infiltration of muscle fibres are also seen. (H & E x100)	136
Fig (5)	Colorectal adenocarcinoma grade III composed mainly of solid sheets of pleomorphic malignant cells showing nuclear atypia in the form of angulation, clumpy chromatin, and prominent nuclei. Also mitoses are seen. (H & E x400)	137
Fig (6)	Colorectal adenocarcinoma grade II infiltrating muscle. (H & E x200)	137
Fig (7)	Colorectal adenocarcinoma infiltrating muscle, showing marked pleomorphism, anisochromatism, and prominent nuclei. (H & E x400)	138
Fig (8)	Colorectal adenocarcinoma infiltrating serosal fat. (H & E x200)	138
Fig (9)	Lymph node showing metastasizing colorectal adenocarcinoma. (H & E x40)	139
Fig (10)	Lymph node involved by adenocarcinoma metastasis. (H & E x100)	139
Fig (11)	Signet-ring cell carcinoma with the cells show large mucin vacuoles filling the cytoplasm and displacing the nucleus. (H & E x200)	140
Fig (12)	Higher magnification of the previous slide showing signet-ring cell carcinoma with the cells exhibiting large mucin vacuoles filling the cytoplasm and displacing the nucleus. (H & E x400)	140
Fig (13)	Mucinous adenocarcinoma showing lakes of mucin with floating mucin secreting malignant epithelial cells & glands, surrounded by desmoplasia. (H & E x100)	141

Fig (14)	Undifferentiated carcinoma. The cells showed pleomorphism, anisochromatism, and hyperchromasia. (H & E x200)	141
Fig (15)	Undifferentiated carcinoma showing anaplastic cells with pleomorphism. (H & E x400)	142
Fig (16)	Brown cytoplasmic staining denoting Bcl-2 expression in grade II adenocarcinoma. (Bcl-2 x400)	142
Fig (17)	Colorectal adenocarcinoma grade II with Bcl-2 cytoplasmic staining. (Bcl-2 x400)	143
Fig (18)	Colorectal adenocarcinoma grade III infiltrating serosal fat showing Bcl-2 immunoreactivity manifested by brown cytoplasmic staining. (Bcl-2 x200)	143
Fig (19)	Signet-ring cell carcinoma showing Bcl-2 immunoreactivity manifested by brown cytoplasmic staining. (Bcl-2 x200)	144
Fig (20)	Signet-ring cell carcinoma showing Bcl-2 brown cytoplasmic staining. (Bcl-2 x400)	144
Fig (21)	Positive nuclear expression of Ki-67 in a case of colorectal adenocarcinoma grade II. (Ki-67 x200)	145
Fig (22)	Colorectal adenocarcinoma grade II with positive nuclear expression of Ki-67. (Ki-67 x200)	145
Fig (23)	Colorectal adenocarcinoma grade II infiltrating serosal fat showing nuclear expression of Ki-67. (Ki-67 x200)	146
Fig (24)	Mucinous adenocarcinoma showing lakes of mucin with floating glands showing nuclear expression of Ki-67. (Ki-67 x200)	146

Table of Contents

Introduction	1
Aim of the Work	3
Review of Literature	4
Large Bowel	4
Anatomy	4
Histology.....	6
Colorectal Carcinoma	9
Incidence.....	9
Colorectal Carcinogenesis	11
Risk Factors	18
Colorectal Cancer Screening	30
Clinical Features	34
Macroscopic Features	35
Histologic Classification of Colorectal Carcinoma.....	36
Histopathologic Types	37
Grading of Colorectal Carcinoma	41
Colorectal Cancer Staging	44
Colorectal Cancer Prognosis	49
Treatment of Colorectal Cancer	58
Bcl-2 Anti Apoptotic Marker	60
Ki-67 Proliferation Marker	66
Material and Methods	75
Results	81
Discussion	147
Summary	160
Conclusion &Recommendation	162
References	163
Arabic Summary	

INTRODUCTION

Colorectal cancer is the third most common cancer and the fourth most frequent cause of cancer deaths worldwide. The WHO estimates that 945,000 new cases occur each year and despite surgical progress, colon cancer is responsible for 490,000 deaths annually in the world (**Weitz *et al.*, 2005**). Colorectal cancer represents the fourth and third most commonly diagnosed type of cancer among men and women respectively (**Jemal *et al.*, 2008**).

Currently, the most useful and widespread method of obtaining a guide to the prognosis in each individual case is through histopathologic confirmation of the adequacy of excision and the tumor stage as assessed by invasion of the tumor through the intestinal wall and determination of lymph node metastasis. This process is the basis for all of the major staging methods used for this particular type of cancer and has been proven to provide the best indication of prognosis. However, it is widely recognized that tumors of the same pathologic stage can produce considerably different clinical outcomes, thereby highlighting the necessity for further identification of other factors that influence prognosis independent of tumor stage (i.e., independent prognostic markers) (**Lyall *et al.*, 2006**).

The rate of cancer growth depends on proliferative activity and tumor cell death rate (**Ustymowicz *et al.*, 2009**). For a long time, dysregulation of cell growth leading to cancer was explained largely in terms of increased cell proliferation. It has become clear now that decreased cell death (apoptosis) may also contribute to the pathologic cell accumulation in a neoplasm. Enhanced cell survival through inhibition of apoptosis may be one of the mechanisms through which tumor promoters exert their effect (**Scopa *et al.*, 2003**).

Bcl-2 oncoprotein inhibits apoptosis both physiologically and pathologically. So the overexpression of Bcl-2 contributes to neoplastic transformation. It was initially found in B-cell follicular lymphomas. Abnormal activation of the Bcl-2 gene is both frequent and early in colon carcinogenesis.
